Status:
COMPLETED
UCB Therapy in Acquired Brain Injury
Lead Sponsor:
MinYoung Kim, M.D.
Conditions:
Acquired Brain Injury
Eligibility:
All Genders
5-15 years
Phase:
PHASE1
Brief Summary
This open label trial is conducted to investigate the efficacy and safety of allogeneic umbilical cord blood (UCB) therapy for patients with acquired brain injury.
Detailed Description
Acquired brain injury (ABI) means brain damage caused by events after birth, rather than as part of a genetic or congenital disorders. Those with ABI suffer from cognitive, physical, or behavioral imp...
Eligibility Criteria
Inclusion
- Acquired brain injury
- Duration: over 12 months
- Willing to comply with all study procedure
Exclusion
- Medical instability including pneumonia or renal function at enrollment
- Uncontrolled persistent epilepsy
- Poor cooperation of guardian,including inactive attitude for rehabilitation and visits for follow-up
- Not eligible according to the principal investigator
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT01885663
Start Date
June 1 2013
End Date
September 1 2016
Last Update
October 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHA Bundang Medical Center, CHA University
Seongnam-si, Gyeonggi-do, South Korea, 463-712